AstraZeneca Plc announced that its experimental pill for hypertension, baxdrostat, achieved more than double the blood pressure reduction of standard therapies in a late-stage clinical trial. The results, unveiled at the European Society of Cardiology meeting in Madrid, mark a significant step forward in tackling a condition that remains one of the leading global health risks.
In the study, the highest daily dose of baxdrostat lowered blood pressure by an average of 15.7 mm Hg over 12 weeks when added to existing hypertension medications. By comparison, patients receiving a placebo alongside standard therapies saw a drop of only 5.8 mm Hg.
Competing in a Crowded Market
The findings strengthen AstraZeneca’s position in the competitive hypertension drug market. Earlier this year, the company had already told investors that baxdrostat produced strong results, but the detailed data now puts it in direct comparison with lorundrostat, a rival medicine developed by Mineralys Therapeutics Inc. Lorundrostat previously showed an 11.7 mm Hg reduction compared to placebo in a major study.
Analysts at UBS had said investor expectations were for results roughly in line with Mineralys’ drug — meaning Astra’s stronger outcome provides a notable edge.
A $5 Billion Opportunity
The UK-based pharmaceutical giant is working to expand its portfolio in cardiovascular and metabolic diseases, including heart conditions and obesity treatments. AstraZeneca estimates that baxdrostat could eventually generate over $5 billion in annual sales if approved.
“The data is going to have a very important impact on patients,” said Ruud Dobber, president of Astra’s biopharmaceuticals unit. He added that the company plans to file for regulatory approval by the end of the year.
Addressing Resistant Hypertension
Roughly 1 in 10 patients suffer from treatment-resistant hypertension, according to the New England Journal of Medicine. Baxdrostat works by blocking the body’s production of aldosterone, a hormone produced by the adrenal glands that regulates salt and water levels. Excess aldosterone makes it harder for the body to excrete salt, leading to elevated blood pressure — a problem that becomes more common with age.
“In my practice, I will be excited about having this drug available,” said Bryan Williams, chair of medicine at University College London and one of the trial’s lead investigators, during a webcast.
Safety and Side Effects
While the results are promising, safety will remain under close watch. Around 3% of patients on high doses developed elevated potassium levels, mostly within the first two weeks of treatment, according to trial researchers. Experts, including cardiologist Isabel Goncalves of Lund University, stressed that more long-term studies are needed to confirm both safety and broader health outcomes.
Rival Therapies in Development
AstraZeneca’s data was presented alongside research from Roche Holding AG and Alnylam Pharmaceuticals Inc., who are developing a twice-yearly injectable treatment for blood pressure. That trial, involving 11,000 patients, will run until 2030 and aims to test not just blood pressure reduction but also whether the therapy improves survival and reduces cardiovascular events.
Goncalves noted that if Roche’s injection proves effective in long-term outcomes, it could revolutionize treatment by reducing reliance on daily pills. “This might help some patients better adhere to medication, as many struggle to take pills every day,” she said.
The Bigger Picture
High blood pressure remains the leading risk factor for heart disease-related deaths worldwide. New therapies like baxdrostat and Roche’s injection could significantly shift how doctors manage the condition in the coming years, offering hope to patients who have struggled with existing medications.
